Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients

Summary

The peri- and postsurgical thromboembolic prophylaxis with low molecular weight heparins is a well established therapy regimen, but the optimum duration of prophylaxis after surgery still remains uncertain. A few studies have pointed to the fact that the thromboembolic risk of high-risk patients persists longer than the in-hospital period correlating with respective hypercoagulatory conditions. The aim of the present study was to test if a prolongation of thromboprophylaxis with the low molecular weight heparin Certoparin further reduces the rate of thromboembolism in high-risk patients after orthopedic surgery. The “Long-term Thromboprophylaxis”-Study was a multicenter, randomized, double-blind, placebo-controlled trial. 360 patients who underwent endoprothetic joint replacement or osteosyn-thesis of the lower limb were initially enrolled, all of them received prophylactically 3000 U anti-Xa of Certoparin once daily for 14 days followed by randomization to prolonged Certoparin application or to placebo up to day 42. Patients were screened for deep vein thrombosis by sonography every week. Coagulation markers (fibrin monomers and D-dimers) were determined during the course of the study.

Venous thromboembolism during the prolongation period was observed in 18 patients receiving placebo versus 8 patients of the prolonged Certoparin group (12.1% versus 5.0%, intention-to-treat sample). The analysis revealed a statistically significant difference in favor of Certoparin (p=0.020), which was confirmed by per-protocol analysis (14.2% versus 5.5%, p=0.012). The differences remained significant, if analyses considered only clinically symptomatic thromboembolic events (p=0.040). Patients who developed a thrombosis showed a strong increase of coagulation markers as compared to patients without subsequent thrombosis. The respective differentiation started around 18 days before diagnosis of thrombosis. Only one minor bleeding complication was observed during prolonged Certoparin prophylaxis.

The present study shows that patients after joint replacement or osteosynthesis of the lower extremities have a persisting risk to develop thromboembolic complications beyond the routine duration of thromboprophylaxis. Extended prophylaxis with Certoparin resulted in a significantly lower rate of thromboembolism and should be strongly recommended.

Keywords

Low molecular weight heparin - prolonged prophylaxis - venous thromboembolism - orthopedic surgery

• References

• 1 Nurmohamed MT, Rosendaal FR, Büller HR. et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
• 2 Leizorovicz A, Haugh MC, Chapuis FR. et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
• 3 Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost 1998; 79: 902-6.
• 4 Koch A, Ziegler S, Breitschwerdt H. et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309.
• 5 McCahill JP, Carrington RWJ, Skinner JA. Current concepts in venous thromboembolism and major lower limb orthopaedic surgery. Int J Clin Pract 2002; 56: 292-7.
• 6 Weitz I J. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
• 7 Hirsh J, Warkentin TE, Raschke R. et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 1998; 114 Suppl 489S-510S.
• 8 Geerts WH, Heit JA, Clagett GP. et al. Prevention of thromboembolism. Chest 2001; 119: 132S-75S.
• 9 Huber O, Bounameaux H, Borst F. et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-3.
• 10 Dahl OE, Aspelin T, Arnesen H. et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
• 11 Galster H, Kolb G, Kohsytorz A. et al. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000; 100: 381-8.
• 12 Bergqvist D, Benoni G, Björgell O. et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
• 13 Planes A, Vochelle N, Darmon J-Y. et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
• 14 Dahl OE, Andreassen G, Aspelin T. et al. Prolonged thromboprophylaxis following hip replacement surgery – results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin^®). Thromb Haemost 1997; 77: 26-31.
• 15 Lassen MR, Borris LC, Anderson BS. et al. Efficacy and safety of prolonged thrombo-prophylaxis with a low molecular weight heparin (dalteparin) after total hip arthrosplasty – the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89: 281-7.
• 16 Hull RD, Pineo GF, Francis C. et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. Arch Intern Med 2000; 160: 2208-15.
• 17 Comp PC, Spiro TE, Friedman RJ. et al. for the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin clinical trial group. J Bone Joint Surg 2001; 83: A336-45.
• 18 Bauer P, Köhne K. Evaluation of experiments with adaptive interim analysis. Biometrics 1994; 50: 1029-41.
• 19 Eriksson I B, Wille-Jørgensen P, Kälebo P. et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
• 20 Lassen MR, Bauer KA, Eriksson I B. et al. for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery. a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
• 21 Heijboer H, Cogo A, Buller HR. et al. Detection of deep-vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. Arch Intern Med 1992; 152: 1901-3.
• 22 Kearon C, Julian JA, Newman BA. et al. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med 1998; 128: 663-77.
• 23 Cohen AT, Bailey CS, Alikhan R. et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty – a meta-analysis. Thromb Haemost 2001; 85: 940-1.
• 24 Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
• 25 Lowe GDO. Prediction of postoperative deep-vein thrombosis. Thromb Haemost 1997; 78: 47-52.
• 26 Lowe GDO, Haverkate F, Thompson SG. et al. on behalf of the ECAT DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. Thromb Haemost 1999; 81: 879-86.